New oral anticoagulant drugs

作者：Berkovits Alejandro^*; Aizman Andres; Zuniga Pamela; Pereira Jaime; Mezzano Diego

来源：Revista Medica de Chile, 2011, 139(10): 1347-1355.

• Anticoagulants
• Haemostasis
• Thrombosis

Thromboembolic disease (TED) is the leading cause of morbidity and mortality worldwide. The hallmark of oral long-term anticoagulant therapy has been the use of vitamin K antagonists, whose anticoagulant effect is exerted inhibiting vitamin K epoxide reductase. Warfarin and acenocoumarol are the most commonly used. In the last five years several new drugs for long term anticoagulation have been developed, which can inhibit single clotting factors with the purpose of improving drug therapeutic range and, ideally, minimizing bleeding risks. This review addresses the state of the art on the clinical use of inhibitors of activated factor X and thrombin. (Rev Med Chile 2011; 139: 1347-1355).

• 出版日期2011-10